IDXX
IDEXX Laboratories, Inc.693.18
-6.95-0.99%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
55.46BP/E (TTM)
54.93Basic EPS (TTM)
12.62Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
IDEXX adds tech-savvy director
IDEXX Laboratories elected Karen Peacock as an independent Class I director effective October 6, 2025, expanding the board from ten to eleven members. Peacock, former CEO of Intercom and ex-SVP at Intuit, brings deep B2B SaaS and AI expertise to bolster IDEXX's innovation in pet diagnostics and software. She joins the Compensation and Talent and Finance Committees. Her skills sharpen board oversight amid evolving tech demands.
10-Q
Q2 FY2025 results
IDEXX Laboratories posted solid Q2 results, with revenue climbing 10.6% year-over-year to $1.11B, fueled by 9.7% organic growth in the core CAG segment where VetLab consumables surged 15.3% on higher volumes and prices. Gross margins expanded 90 basis points to 62.6%, thanks to productivity gains offsetting inflation, while operating income jumped 41.4% to $373M after shedding a one-time litigation hit from last year. Diluted EPS rose 48.8% to $3.63, aligning with 80,994 weighted shares. Cash from operations held steady at $424M year-to-date, but heavy stock buybacks totaling $739M pushed net cash down; debt sits at $1.1B with $669M revolver room and no covenant issues. Free cash flow came in at $360M (derived). Yet competition in diagnostics could squeeze margins if pricing softens.
IPO
Website
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
CODX
Co-Diagnostics, Inc.
0.25-0.02
CRL
Charles River Laboratories Inte
195.22-2.93
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
LH
Labcorp Holdings Inc.
258.11-5.22
NEOG
Neogen Corporation
7.04+0.19
WAT
Waters Corporation
378.53-6.89